Repetitive transcranial magnetic stimulation for treatment-resistant depression: OHTAC recommendation

Health Quality Ontario

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors’ conclusions
OHTAC recognizes that electroconvulsive therapy (ECT) is the most effective treatment for non-psychotic, treatment-resistant depression. OHTAC therefore recommends that repetitive transcranial magnetic stimulation be publicly funded for patients with nonpsychotic, treatment-resistant depression only when ECT is not an option. Health Quality Ontario conducted a review to determine the clinical effectiveness of rTMS compared to either electroconvulsive therapy or sham treatment. In addition, Health Quality Ontario worked with the Programs for Assessment of Technology in Health (PATH) Research Institute to evaluate cost-effectiveness and one-year budgetary impact of the technology.

Final publication URL

Indexing Status
Subject indexing assigned by CRD

MeSH
Humans; Depression; Depressive Disorder, Treatment-Resistant; Transcranial Magnetic Stimulation; Treatment Outcome

Language Published
English

Country of organisation
Canada

Province or state
Ontario

English summary
An English language summary is available.

Address for correspondence
Evidence Development and Standards, Health Quality Ontario, 130 Bloor Street West, 10th floor, Toronto, Ontario Canada M5S 1N5 Email: EDSinfo@hqontario.ca

AccessionNumber
32016000560

Date abstract record published
22/03/2016